Navigation Links
Cephalon Notified of Generic Fentanyl Buccal Tablet Filing
Date:4/24/2008

ta. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride), FENTORA, TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800- 896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including whether the company will initiate a patent infringement lawsuit against Watson; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions aff
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015   University of Maryland (UM) Ventures ... the signing of an exclusive option by Biomecite Diagnostics ... to develop diagnostics to detect inflammatory bowel diseases (IBD), ... Drs. Florian Fricke and James White ... the University of Maryland School of Medicine,s Institute for ...
(Date:5/6/2015)... Histogen, Inc., a regenerative medicine ... cells grown under simulated embryonic conditions, will present ... for melanoma during the 2015 Society of Investigative ... 2015 in Atlanta, GA. , Histogen has previously ... material with anti-oncologic properties, with potential benefit in ...
(Date:5/5/2015)... AND TORONTO, May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... reported financial results for the three months ended March ... otherwise, all amounts are in Canadian dollars. ... fiscal year end from May 31 to December 31. ... period being reported is for the three months ended ...
(Date:5/5/2015)... 2015 Research and Markets ... of the "Separation Systems Market in ... Macromolecules which include protein, RNA, DNA ... broken into smaller molecules, during production of ... various advanced systems like centrifugation, liquid chromatography, ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2
... , , ... CypHer5 TM is a red-excited, pH-sensitive cyanine dye that is ... is therefore ideally suited for monitoring internalization of cell surface receptors ... <P ,>In the assay, the receptor can ...
... Key words: adenoviral vector ... delivery, , ... can greatly aid secondary screening as well as lead and target ... to express target genes of interest at detectable levels takes time. ...
... , , , ... binding assay • LEADseeker • SPA Imaging Beads, ... are present in high levels in the pituitary and are processed ... hormones, and β-endorphin. The various melanocyte stimulating hormones are known to ...
Cached Biology Technology:The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 2The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 3The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 4The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 5The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... not want to live a long and healthy life? A ... from ETH Zurich have demonstrated in roundworms. Vitamin B3 ... the worms, diet caused them to live for about one ... of researchers headed by Michael Ristow, a professor of energy ...
... a new treatment for glioblastoma suggest that researchers may ... aggressive of brain tumours, as well as a potential ... to treatment. Presenting the research to the 2013 ... Wick will say that combining radiotherapy with an anti-cancer ...
... particularly neuroproteins that maintain proper brain function. ... known as "tangle diseases" because they are characterized by ... A team of Australian and American scientists discovered ... inserted into neuroproteins, causing them to misfold and aggregate. ...
Cached Biology News:Niacin, the fountain of youth 2Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 2Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 3New mechanism for protein misfolding may link to ALS 2
... revolutionizes imaging software for the microscopy ... microscopes, cameras, components and peripherals with ... tools. Its intuitive interface simplifies workflow ... while providing powerful features such as ...
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... incorporates the critical design features demanded by ... research. The Series 4000 delivers improved performance, ... discoveries to biomarker assays all on the ... to fit into the research plans of ...
Biology Products: